INTRODUCTION
Isogenic molecular clones were derived from pNL4-3 (HIV-WT; NIH AIDS Reagent 139 Program, cat. 114) (43), Replication competent molecular clones encoding Vif mutants 140 E45G (HIV-45G) and SLQ144AAA (HIV-ΔSLQ) were generated as previously described 141 (44) . Viral stocks were generated by transfecting HEK293T cells using 4μg/mL 142 polyethylenimine (PEI, Polysciences Inc., cat. 23966). Culture supernatants were collected 143 48 hours post-transfection, filtered and frozen at -80°C until further use. Viral stock 144 concentrations were quantitated using an in-house p24 ELISA (45) and/or tittered on TZM-145 bl reporter cells as previously described (44) . 146
Generation of humanized mice 147
Animals were housed under specific pathogen free conditions. Humanized mice were 148 generated as previously described (29) . Briefly, newborn immunodeficient NOD-scid IL-149 2Rγ-null (NSG) mice (Jackson laboratory, Bar Harbor, ME) were irradiated 1-3 days after 150 birth with 1 Gy and transplanted intrahepatically with approximately 2.0±0.5×10 5 cord blood-151 derived CD34+ cells. Between 2 and 6 mice were transplanted with cells from the same 152 donor. A total of 12 donors were used for the three infection experiments. 153
Twelve to sixteen weeks after transplantation, human engraftment and de novo human 154 immune system reconstitution in the mice were assessed by staining peripheral blood with 155 monoclonal antibodies against the panhuman marker CD45 (Beckman Coulter, cat. 156 B36294), CD19 (Biolegend, cat. 302212), CD3 (Biolegend, cat. 300308), CD4 (Biolegend, 157 cat. 300518) and CD8 (Biolegend, cat. 301035). Flow-cytometry analyses were performed 158 on a CyAN™ ADP Analyzer (Beckman Coulter, Brea, CA). 159
Infection and antiretroviral treatment of humanized mice 160
Mice were infected intraperitoneally with 2×10 5 TCID50 per mouse of each of the 3 HIV 161 clones in 200μL volume. Plasma viremia was measured using Cobas® Amplicor technology 162 (Roche, Switzerland) at the described time points throughout the infection. The detection 163 limit of the assay is 400 HIV RNA copies/mL. 164
Lamivudine (3TC Epivir, GlaxoSmithKlein, UK) treatment was started 30 days post infection 165 in the treatment group of the infected mice. 3TC tablets were weighed, pulverized and 166 combined with food pellets as previously described (29) . 167
Amplification of HIV from plasma viral RNA 168
Viral RNA was extracted from 140μL frozen plasma using the QIAamp Viral RNA Minikit 169 (QIAGEN, cat. 52904) as per manufacturer's instruction. 170
For deep sequencing, cDNAs were synthesized using custom reverse transcription 171 primers.(Supplemental Table 1 ; Integrated DNA Technologies). From 5' to 3', our first 172 generation RT cDNA primer (4372) included a 16 basepair (bp) HIV-specific sequence 173 (accession: AF324493.2: 3336-3351), 8 bp randomized sequence (unique molecular ID 174 (UMID)) and an additional 23 bp HIV-specific sequence (AF324493.2: 3305-3327). Viral 175 cDNA was synthesized using the Invitrogen TM ThermoScript RT-PCR System (Thermo 176 Fisher Scientific, cat. 11146016). Briefly, RNA and primer were denatured at 65°C for 5 min. 177
ThermoScript reaction mix was added to the RNA and primer and incubated at 50°C for 60 178 min, followed by an inactivation step of 85°C for 5 min. 179 Viral cDNA was column purified (Zymo Clean and Concentrator kit, cat. D4034) and 180 amplified in a first round PCR using primers 1922 (AF324493.2: 2929-2946) and 1923 181 (AF324493.2: 3337-3356). First round PCR used Pfx50 polymerase (94°C for 2 min, 182 followed by 23 cycles of 93°C for 15 sec, 48°C for 30 sec, 68°C for 60 sec and a final 183 extension of 68°C for 10 min) (Thermo Fisher Scientific, cat. 12355012). First round 184 products were purified (Zymo Clean and Concentrator) and a second PCR was performed 185 to add Illumina-based adapters using custom primers 1690 and one of 73 primers with 186 distinct MiSeq barcode identifiers (Supplemental Table 1 Table 1 ). 213
Bioinformatic Pipeline for Sequence Analyses 214
Custom Unix and Perl scripts were written to process FASTQ files. First, paired-end reads 215 were merged using Paired-End reAd mergeR (46). Reads were aligned to pNL4-3 RT or vif 216 reference sequences (AF324493.2) and filtered. Sequences were grouped by distinct 217 UMIDs. A minimum of three high quality merged pair-end reads contained the same UMID 218 were required to generate a consensus sequence. Consensus sequences were defined as 219 sequences where each nucleotide reflected 70% or more of all nucleotides sequenced for 220 that given position. Consensus sequences for sequences defined by a distinct UMID were 221 identified using in-house scripts. Twenty-five UMIDs that differed by only one mismatch 222 from the HIV template sequence were considered to be experimental artifacts and excluded 223 from the analyses. 224
Additional custom scripts were written to identify 3TC resistance mutations at RT codon 184 225 and to compute overall mutation rates, GG-to-GA as well as GA-to-AA mutagenesis and 226 the frequency of stop codons within the sequenced RT and vif regions. DNASP v5 227 polymorphism software was used to calculate the nucleotide diversity (π), defined as the 228 average pair-wise number of nucleotide differences per site in all possible pairs of 229 consensus sequences per sample (47). 230
Statistics 231
Normality was assessed using the D'Agostino and Pearson test for numerical data such as 232 baseline plasma viremia, changes in viremia, proportions of 3TC susceptible/resistant viral 233 sequences, nucleotide diversity, and mutation rates. If groups passed normality tests, 234 parametric student's t-test for unpaired data or paired student's t-test for paired data were 235 used. Otherwise, non-parametric Mann-Whitney or Wilcoxon matched pairs signed-rank 236 tests were used. For categorical data (e.g., treatment failure/success), Fisher's exact test 237 was used. Linear regression models were used for replication kinetics and F-tests were 238 used to compare slopes of curves of best fit. Finally, nonlinear regression methods 239 (exponential (Malthusian)) using weighted least squares were used with extra sum-of-240 squares F-test to compare nonlinear curves of best fit. 241
Significance testing is reported as exact p-values in the text or using asterisks (*, p ≤ 0.05; 242 **, p ≤ 0.01; ***, p ≤ 0.001; ****, p ≤ 0.0001). All statistics were performed using the built-in 243 analysis packages from GraphPad Prism v7.0 Suite (GraphPad Software, Inc, La Jolla, CA). 244
Data availability 245
All processed FASTA sequencing files are publicly available (will be released upon 246 publication). In addition, in-house codes for sequence read processing can be accessed at 247 https://github.com/AceM1188/Vif-pipeline. 248 Experiment 2 (4-7 day versus 14 day intervals). 304
RESULTS

249
HIV-WT and HIV-45G establish productive infection in the humanized mouse model
The initial virological response upon 3TC initiation was comparable between the two 305 groups. Within the first two weeks of 3TC treatment both HIV-WT and HIV-45G viremia 306 decreased to comparable nadirs (0.69 log10 versus 0.66 log10, respectively) ( Fig. 2C) . One 307 mouse (#120, infected with HIV-45G) was euthanized at Day 44 post infection as per animal 308 safety protocol due to signs of wasting. Considering the overall change from baseline to 309 experiment termination, HIV-WT replication decreased by 0.55 log10 in the presence of 3TC, 310 whereas HIV-45G viremia had increased by 0.25 log10 from baseline (p=0.0045) ( Fig. 2D) . 311
Moreover, HIV-45G infected animals experienced a larger (0.99 log10 vs. 0.52 log10, 312 p=0.0068, Fig. 2E ) and faster (0.061 vs. 0.033 log10/day, p=0.0052, Fig. 2F ) viral rebound 313 from the initial lowest points reached upon 3TC treatment initiation. 314
We also assessed 3TC treatment outcomes in a qualitative manner (e.g., treatment 315 success versus failure, with success being defined as sustained reduction in viremia with 316 less than 0.5 log10 rebound from the lowest points). Antiviral treatment was successful in 317 64% of HIV-WT infected mice but only 9% of HIV-45G infected mice ( Fig. 2G) . Thus, HIV-318 45G infected mice had a significantly higher risk of failing treatment (RR: 7.000; 95% CI 319 1.482 -40.54; p=0.0237). 320 Taken Fig. 3A) . These substitutions confer up to >1,000-fold reduced susceptibility to 3TC (53, 332 58). Both mutations can result from reverse transcription errors, although the mutation 333 leading to RT-184I is also within a dinucleotide context favored for A3G driven mutagenesis 334 (e.g., GG-to-AG mutations, (ATGG->ATAG))(55, 60). 335
To further investigate the in-vivo dynamics of resistance appearance, we used a 336 next generation sequencing approach to analyze a 250 bp region of HIV RT (codon 177 to 337 258) from cell-free HIV RNA (vRNA) present in the plasma compartment. We combined a (Fig. 3D) . 370
Thus, emergence of viral variants with RT-184I is favored over that of RT-184V variants in 371 animals infected with a virus displaying suboptimal A3G neutralization activity. Of note, 372 M184I variants also appear often prior to M184V variants in 3TC treated patients (53, 58) . 373
Characterization of RT sequence diversity throughout the course of infection 374
We next determined sequence diversity within the sequenced RT region beyond the 375 3TC drug resistance associated codon 184. We calculated the nucleotide diversity (π) 376 among unique RT variants within a given plasma sample (63-65). 377
Prior to 3TC treatment (Day 30 post infection), mice infected with HIV-WT and HIV-378 45G showed comparable nucleotide diversity in RT (p=0.6308, Fig. 4A ). However, when 379 we assessed the relationship between RT nucleotide diversity and the plasma viral load 380 measured at Day 30 (prior to treatment initiation), we noted that nucleotide diversity 381 positively correlated with the level of plasma viremia in HIV-45G infected animals ( Fig. 4C ) 382 while the opposite was true for HIV-WT infected animals (Fig. 4B) . For this analysis we 383 assumed an exponential (Malthusian) relationship based on the nature of HIV growth and 384 diversity in acute infection (66, 67). 385
We next explored how RT sequence diversity changed throughout the course of 386 infection. While RT diversity remained largely unchanged in treatment-naïve animals, both 387
HIV-WT and HIV-45G diversity in treated animals initially increased but then stabilized (Day 388 44 post infection, Fig. 4D-E) . RT sequence diversity in 3TC treated mice was driven by drug 389 resistance associated mutations. Indeed, mutations at RT codon 184 contributed to 49-390 74% of HIV-WT and 45-69% of HIV-45G diversity (data not shown). When we excluded 391 codon 184 from π analyses, any increases in diversity from baseline to Day 44 through Day 392 75 were lost in the HIV-WT infected mice (p³0.3097). However, when we did the same for 393 HIV-45G infected mice, HIV-45G viruses displayed a significant increase in diversity starting 394 at Day 58 through Day 75 post infection (p£0.0430, Mann-Whitney). Thus, while the 395 observed increase in RT sequence diversity is mainly due to selection of 3TC resistant 396 variants, other sites within RT contribute to viral diversity in HIV-45G infected mice. 397
However, these non-drug resistance associated changes in HIV-45G viruses are only 398 observed at later time points suggesting that they require more time to appear. 399
Next, we explored the contribution of APOBEC3-driven mutagenesis to the RT 400 sequence diversity. Towards this end, we measured G-to-A mutations within APOBEC3-401 specific dinucleotide motifs (e.g., A3G: GG-to-AG; A3D/A3F: GA-to-AA, (68)). The 250 bp 402 long region of RT that we sequenced contains 15 GG and 25 GA dinucleotides that could 403 serve as APOBEC3 target motifs. At Day 30 post infection (prior to 3TC treatment), both 404 differences were only significant for the HIV-45G infected animals (p=0.0020, Fig. 5A) . At 406
Day 58 post infection in treated mice (Fig. 5C) , GG-to-AG rates were higher than GA-to-AA 407 rates in both HIV-WT (p=0.0078) and HIV-45G (p=0.0020) infected mice. GG-to-AG 408 mutation rates in HIV-WT and HIV-45G mice were comparable (p=0.6965) and were not 409 due to selection of the RT-184I as rates were still comparable after analyses of sequences 410 with codon 184 excluded (p=0.3445, Mann-Whitney). 411
Due to its preferred dinucleotide context, A3G-induced mutagenesis can introduce 412 mutations resulting in premature stop codons (e.g., UGG-to-UAG, (7, 69, 70)). Given that 413 premature stop codons within RT are deleterious to replication (71-76), we were surprised 414 to see that most infected animals (10/14 HIV-WT, 11/12 HIV-45G) had, at least, one plasma 415 viral genome with mutations resulting in a stop codon upon protein translation. HIV-WT and 416
HIV-45G viral populations in the plasma displayed stop codons predominantly at the four 417 tryptophan (UGG-to-UAG or -UGA) codons (e.g., W212, W229, W239, W252) and rarely, 418 at one of the six glutamine encoding codons (CAG-to-UAG, CAA-to-UAA; Q182, Q197, 419 Q207, Q222, Q242, Q258). Of the 155,462 unique RT analyzed, 868 carried mutations 420 leading to premature stop codon. The majority of the RT sequences (85%) only had a single 421 stop codon but a small portion of sequences had two (11%), three (3%) or, at most, four 422 (1%) stop codons. The rate of stop codons at Day 30 and at Day 58 post infection was, 423 however, comparable between the two groups (p=0.1294, Fig. 5B; p=0.1211, Fig. 5D ). 424 425
Characterization of vif sequence diversity throughout the course of infection 426
Lastly, we were interested in the extent to which the vif sequences changed over 427 the course of infection. We used samples remaining from a subset of 14 animals included 428 in Experiment #3 to sequence a 268 bp long region of HIV vif (corresponding with codons 429 23 to 112) using a sequencing approach comprising UMID and Illumina 150 bp pair-end 430 sequencing technology analogous to the approach taken for analyzing RT sequence 431 diversity. In total, we generated 579,466 high quality paired-end reads representing 6,983 432 distinct UMIDs from 27 plasma vRNA samples. 433
We first looked for evidence of HIV-45G revertants at Day 30 and Day 58 post 434 infection in five Vif-45G infected animals (Fig. 6A) . Viruses in HIV-45G infected animals 435 carrying the Vif-45E reversion were rare at Day 30 post infection (less than 1% in all five 436 animals) but ranged between 0.5% and 9% of the plasma virus population present at Day 437 58 post infection (Fig. 6A) . These data suggest that the Vif-45G genotype is quite stable 438 over time. 439 Since it has been suggested that vif diversification may be distinct from that of other 440 HIV genes depending on the selective pressures exerted (7, 70, 77), we analyzed the 441 nucleotide diversity, APOBEC3 driven mutagenesis and the rate of stop codons for the vif 442 region sequenced (Figs. 6B-6G) . The 268 bp long region of vif that we sequenced contains 443 17 or 18 GG (HIV-WT, Vif E45 = GAA; HIV-45G, Vif E45G = GGA) and 22 GA dinucleotides 444 that could serve as APOBEC3 target motifs. Prior to treatment (Day 30 post infection), vif 445 sequence diversity (Fig. 6B) , GG-to-AG/GA-to-AA mutation rates ( Fig. 6C) and stop codon 446 frequency ( Fig. 6C) were comparable between HIV-WT and HIV-45G infected mice. Previous studies in cell culture (20, 44, 87) and in humanized mice (33-37) have 471 examined the role of APOBEC3 proteins in HIV replication and pathogenesis in vivo but our 472 study dissects the impact of A3G-driven mutagenesis in the context of viral evolution by 473 introducing selection in the form of antiretroviral treatment. Moreover, we focus on viral 474 diversification within the plasma compartment, which reflects the actively replicating viral 475 quasispecies in an immediate and dynamic manner. HIV-45G, which has suboptimal anti-476 A3G activity, is less fit than HIV-WT in treatment-naïve animals overtime ( Fig. 2A) pointing 477 to the slow accumulation of mutations that fail to provide any evolutionary benefit given that 478 hu-NSG mice lack immunologic pressures (i.e., CD4+/CD8+ T cell responses or antibodies 479 (88)). Conversely, HIV-45G responds less well and rebounds more rapidly in the presence 480 of 3TC treatment (Figs. 2B-2D) . Thus, complete inactivation of A3G is dispensable for 481 initiating a productive and robust infection of humanized mice and suboptimal A3G 482 neutralization can be beneficial to HIV for overcoming evolutionary bottlenecks such as 483 selection pressure by antiretroviral drugs. 484
Sequencing technologies have dramatically improved over the last decade allowing 485 for high-resolution, accurate representation of viral quasispecies. We combined UMIDs with 486
Illumina pair-end sequencing to analyze >150,000 individual RT sequences sampling 487 approximately 1,170 distinct viral genomes for each individual time point. Previous studies 488 in humanized mice examined sequence diversity using bulk amplification followed by 489 sequencing of individual clones (33-36) or by single-genome sequencing (SGS, (36)). The 490 first of these methods fails to reliably distinguish between individual variants and may skew 491 viral diversity measurements due to PCR errors or bias (61, 62). SGS is regarded as gold 492 standard in the field since it analyses distinct genomes and provides information on large 493 regions. However, the approach is very work intensive and costly, limiting the numbers of 494 genomes that can be sampled (89-91). For example, one previous study used SGS to 495 analyze a total of 265 genomes from eight mice (36). In our study, in contrast, we analyzed 496 on average 1,400 RT sequences per infected animal providing us with solid data on minority 497 viral populations. It has to be noted that even at our high sequencing depth, we only sample 498 a limited portion of the viruses circulating in the plasma compartment (i.e., average plasma 499 viremia at Day 30 post infection is 89,620 copies/mL). Despite this limitation, our 500 sequencing data revealed a number of previously overlooked facts regarding the dynamics 501 of HIV evolution in vivo. First, we found that 3TC drug resistant viral variants were found, in 502 a third of the animals, prior to 3TC treatment initiation (Fig. 3B) . Pre-existing 3TC resistance 503 was, however, not linked to more rapid treatment failure suggesting that these viruses may 504 not be replication competent. Second, we noted a positive correlation between increased 505
RT sequence diversity and high plasma viremia in HIV-45G infected animals after 30 days 506 of unchecked replication (Fig. 4B) . This association is surprising since conventional wisdom 507 would predict the opposite to be true. Indeed, this is exactly what we observe for HIV-WT 508 infections where increased RT diversity is associated with lower plasma viremia (Fig. 4C) . 509
Third, the kinetics with which the two drug resistant variants RT-184I and RT-184V 510 appeared in the plasma differed between the two viruses. In mice infected with HIV-45G, 511 the RT-184I variants arose at a rate 8.3-times faster than that of RT-184V variants, whereas 512 emergence rates for these variants were comparable in mice infected with HIV-WT ( Fig.  513   3D) . However, RT-184I did not appear more readily in HIV-45G infected animals. This could 514 be due to the fact that our earliest collection time point was ten days after treatment 515 initiation. It is also conceivable that drug resistant variants first evolve, replicate and expand 516 in tissue compartments with the plasma compartment being a mere reflection after the fact. 517
Taken together, future studies investigating the viral diversification at the viral 518 RNA, cellular viral RNA and proviral level in vivo in the humanized model will provide 519 further insights into how viral quasispecies shaped by APOBEC3 mutagenesis inform on 520
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